New Sale of LexaGene’s MiQLab™ System Propels Early Diagnostic Testing in Veterinarian Practices
June 24 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), a
molecular diagnostics company that develops fully automated rapid
pathogen detection systems, today announced Meridian Veterinary
Capital, LLC (“Meridian”) has purchased a MiQLab System to be used
by the emergency and specialty veterinary hospitals they support
with locations across the country.
Dr. Jack Regan, LexaGene’s CEO and Founder stated, “We’re
thrilled to welcome Meridian to our customer portfolio. We continue
to see traction in the veterinary market and expect this to build.
Time and time again, we hear from our early adopters that the
MiQLab boosts the confidence veterinarians have in making an
initial diagnosis and prescribing the right therapy for any
detected pathogen. Our customers love having a system in their own
facility that can largely replace the need to send samples off-site
to a reference laboratory where it takes days to get results back.
Our goal is that LexaGene will be recognized as the trusted,
go-to-provider for veterinary in-clinic pathogen detection
solutions.”
MiQLab is an easy to use, sample-to-answer microbial detection
system for a wide range of point-of-need applications. It provides
fast, accurate, and reliable detection of up to 27 pathogens and
antimicrobial resistance markers at once. Meridian purchased a
MiQLab to reduce the turnaround time for diagnostic testing so that
their veterinary partners can make evidence-based medical care
decisions soon after seeing a sick pet. Veterinarians using MiQLab
for in-clinic testing have increased confidence in prescribing the
most appropriate antibiotic and keeping pet owners at ease knowing
their loved ones are receiving the best possible care.
Dr. Regan added, “LexaGene’s MiQLab System is the start of a
technology wave that is sweeping through veterinary care. We
listened to our veterinary partners and developed the MiQLab System
to help meet their point-of-care diagnostic needs. Fast and
reliable diagnostic results translate into improved therapeutic
treatments for our companion animals.”
Meridian is a Dallas, Texas based real estate investment and
development firm that provides custom building solutions for animal
health professionals. Meridian’s focus is on the advancement of pet
healthcare—by helping veterinary specialty practice operators and
other animal care providers design, build, and finance efficient,
comfortable, and cost-effective care facilities that have
state-of-the art diagnostic and treatment capabilities. To learn
more about Meridian and its operating partners, click here.
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing, and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Contact:
ir@lexagene.com
800.215.1824
Media Contact:
Gail Winslow
Director of Corporate Marketing
gwinslow@lexagene.com
978.482.6237
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024